A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein (NS5A) resistance-associated variants. Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks will be prescribed.
Name: daclatasvir
Description: to evaluate the treatment efficacy and safety of the drug in HCV patientsType: DrugStudy Arm
Name: asunaprevir
Description: to evaluate the treatment efficacy and safety of the drug in HCV patientsType: DrugStudy Arm
Name: Ribavirin
Description: to evaluate the treatment efficacy and safety of the drug in HCV patientsType: DrugStudy Arm
Description: SVR12 is defined as undetectable HCV RNA 12 weeks throughout 12 weeks of post-treatment follow-up peroid
Measure: To determine the treatment efficacy (SVR12) of 12 weeks of daclatasvir and asunaprevir plus ribavirin for HCV-1b patients without baseline RAVs Time: 6 months (including 3 months of treatment and 3 months of post-treatment follow-up peroidSingle Group Assignment
There are 2 SNPs
The existence of baseline NS5A RAV "Lycine 31 (L31F/I/M)" or "Tyrosine93 (Y93H)", by using direct-sequencing with RAV of > 20%. --- L31F ---
The existence of baseline NS5A RAV "Lycine 31 (L31F/I/M)" or "Tyrosine93 (Y93H)", by using direct-sequencing with RAV of > 20%. --- L31F --- --- Y93H ---